Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

被引：7
作者：
Sorel, Nathalie
Roy, Lydia
Martineau, Geraldine
Guilhot, Francois
Turhan, Ali G.
Chomel, Jean-Claude
机构：
[1] CHU Poitiers, Lab Hematol, F-86021 Poitiers, France
[2] CHU Poitiers, EA 3805, F-86021 Poitiers, France
来源：
BLOOD | 2006年 / 108卷 / 05期
关键词：
D O I：
10.1182/blood-2006-03-011668
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1782 / 1783
页数：2
相关论文
共 8 条
  • [1] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Segal, GM
    Fanning, S
    Zimmermann, J
    Lydon, NB
    [J]. NATURE MEDICINE, 1996, 2 (05) : 561 - 566
  • [2] Drug resistance in cancer: Principles of emergence and prevention
    Komarova, NL
    Wodarz, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (27) : 9714 - 9719
  • [3] Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells
    Luzzatto, L
    Melo, JV
    [J]. BLOOD, 2002, 100 (03) : 1105 - 1105
  • [4] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    O'Brien, SG
    Guilhot, F
    Larson, RA
    Gathmann, I
    Baccarani, M
    Cervantes, F
    Cornelissen, JJ
    Fischer, T
    Hochhaus, A
    Hughes, T
    Lechner, K
    Nielsen, JL
    Rousselot, P
    Reiffers, J
    Saglio, G
    Shepherd, J
    Simonsson, B
    Gratwohl, A
    Goldman, JM
    Kantarjian, H
    Taylor, K
    Verhoef, G
    Bolton, AE
    Capdeville, R
    Druker, BJ
    Durrant, S
    Schwarer, A
    Joske, D
    Seymour, J
    Grigg, A
    Ma, D
    Arthur, C
    Bradstock, K
    Joshua, D
    Louwagie, A
    Martiat, P
    Straetmans, N
    Bosly, A
    Shustik, C
    Lipton, J
    Forrest, D
    Walker, I
    Roy, DC
    Rubinger, M
    Bence-Bruckler, I
    Kovacs, M
    Turner, AR
    Birgens, H
    Bjerrum, O
    Facon, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) : 994 - 1004
  • [5] Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    Shah, NP
    Nicoll, JM
    Nagar, B
    Gorre, ME
    Paquette, RL
    Kuriyan, J
    Sawyers, CL
    [J]. CANCER CELL, 2002, 2 (02) : 117 - 125
  • [6] Overriding imatinib resistance with a novel ABL kinase inhibitor
    Shah, NP
    Tran, C
    Lee, FY
    Chen, P
    Norris, D
    Sawyers, CL
    [J]. SCIENCE, 2004, 305 (5682) : 399 - 401
  • [7] Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients
    Sorel, N
    Chazelas, F
    Brizard, A
    Chomel, JC
    [J]. CLINICAL CHEMISTRY, 2005, 51 (07) : 1263 - 1266
  • [8] High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
    Willis, SG
    Lange, T
    Demehri, S
    Otto, S
    Crossman, L
    Niederwieser, D
    Stoffregen, EP
    McWeeney, S
    Kovacs, I
    Park, B
    Druker, BJ
    Deininger, MW
    [J]. BLOOD, 2005, 106 (06) : 2128 - 2137
1